Abstract
Chronic hepatitis D (CHD) results from an infection with the hepatitis B virus and hepatitis D virus (HDV). CHD is the most severe form of human viral hepatitis. Current treatment options consist of interferon alfa, which is effective only in a minority of patients. Study of HDV molecular virology has resulted in new approaches entering clinical trials, with phase-3 studies the most advanced. These include the entry inhibitor bulevirtide, the nucleic acid polymer REP 2139-Ca, the farnesyltransferase inhibitor lonafarnib, and pegylated interferon lambda. This article summarizes the available data on these emerging therapeutics.
Keywords:
Cirrhosis; Clinical trials; Hepatitis B; Hepatitis D; Therapeutics.
Published by Elsevier Inc.
Publication types
-
Research Support, N.I.H., Intramural
-
Review
MeSH terms
-
Antiviral Agents / therapeutic use
-
Clinical Trials, Phase III as Topic
-
Coinfection / drug therapy*
-
Drugs, Investigational / pharmacology
-
Drugs, Investigational / therapeutic use
-
Female
-
Hepatitis B virus / drug effects*
-
Hepatitis B virus / isolation & purification
-
Hepatitis B, Chronic / diagnosis
-
Hepatitis B, Chronic / drug therapy
-
Hepatitis B, Chronic / epidemiology
-
Hepatitis D, Chronic / diagnosis
-
Hepatitis D, Chronic / drug therapy*
-
Hepatitis D, Chronic / epidemiology
-
Hepatitis Delta Virus / drug effects*
-
Humans
-
Interferon-alpha / therapeutic use*
-
Male
-
Piperidines / therapeutic use
-
Polyethylene Glycols / therapeutic use*
-
Prognosis
-
Pyridines / therapeutic use
-
Recombinant Proteins / therapeutic use
-
Risk Assessment
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Drugs, Investigational
-
Interferon-alpha
-
Piperidines
-
Pyridines
-
Recombinant Proteins
-
Polyethylene Glycols
-
lonafarnib
-
peginterferon alfa-2a